カテゴリ： GlobalData, アメリカ, 企業調査

Amgen Inc (AMGN)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Amgen Inc (AMGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7228
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：106
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc (AMGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Amgen Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Amgen Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 10
Amgen Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Amgen Inc, Medical Equipment, Deal Details 13
Venture Financing 13
Gamida Cell Raises US$10 Million In Series E Financing 13
Partnerships 15
Biocartis Enters into Development Agreement with Amgen 15
Biocartis Enters into Co-Development Agreement with Amgen 16
Adaptive Biotechnologies Enters into Agreement with Amgen for Multiple Myeloma 17
Adaptive Biotech Enters into Agreement with Amgen 18
Biocartis Partners with Amgen 19
Exosome Diagnostics Enters into Agreement with Amgen 20
Flatiron Health Partners with Amgen 21
Biocartis Enters into Agreement with Amgen 22
Dako Enters into Co-Development Agreement with Amgen for Companion Diagnostic 23
Dako Enters Into Co-Development Agreement With Amgen For Molecular Diagnostic Test 24
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 25
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 26
KineMed Enters Into Co-Development Agreement With Amgen For Kinetic Biomarkers Of Brain Proteinopathies 27
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 28
Dako Enters Into Co-Development Agreement With Amgen 29
Dako Enters Into Co-Development Agreement With Amgen 30
Merger 31
AstraZeneca Rumored To Merge With Amgen 31
Amgen Enters into Licensing Agreement with Unilife 32
Debt Offering 33
Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 33
Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 34
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 35
Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 37
Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 38
Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 39
Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 40
Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 41
Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 42
Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 43
Unilife Raises USD30 Million in First Tranche of Private Placement of 6% Senior Secured Convertible Notes Due 2023 44
Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 46
Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 47
Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 48
Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 49
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 50
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 52
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 54
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 56
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 58
Acquisition 60
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 60
Amgen Inc – Key Competitors 62
Amgen Inc – Key Employees 63
Amgen Inc – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Joint Venture 70
Recent Developments 72
Strategy And Business Planning 72
Apr 10, 2018: Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant 72
Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 73
Financial Announcements 74
Jul 26, 2018: Amgen reports second quarter 2018 Financial Results 74
Apr 24, 2018: Amgen Announces First Quarter 2018 Financial Results 77
Feb 01, 2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results 79
Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 82
Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 84
Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 86
Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 89
Corporate Communications 92
Jul 26, 2018: Amgen Announces Succession Plans For Two Executive Officers 92
Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires 93
Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 94
Sep 22, 2017: Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 95
Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 96
Government and Public Interest 97
Jul 11, 2017: Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket 97
Other Significant Developments 98
Sep 24, 2018: MedTech Innovator announces newest industry partners 98
Sep 20, 2018: Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub – BioLA 99
Sep 10, 2018: Amgen selects Deloitte to provide an integrated patient services platform 100
Mar 08, 2018: Amgen Announces Final Results Of Tender Offer 101
Mar 06, 2018: Amgen Announces Preliminary Results Of Tender Offer 102
Sep 25, 2017: Amgen Provides Update On Hurricane Maria 103
Mar 29, 2017: Amgen Enters into Agreement with Inovalon and Avalere to Engage Value-based Contracting Opportunities 104
Jan 09, 2017: DaVita Enters Into New Sourcing and Supply Agreement with Amgen and Initiates 2017 Kidney Care Guidance 105
Appendix 106
Methodology 106
About GlobalData 106
Contact Us 106
Disclaimer 106

List of Tables
Amgen Inc, Medical Equipment, Key Facts, 2017 2
Amgen Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Amgen Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Amgen Inc, Deals By Market, 2012 to YTD 2018 10
Amgen Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Gamida Cell Raises US$10 Million In Series E Financing 13
Biocartis Enters into Development Agreement with Amgen 15
Biocartis Enters into Co-Development Agreement with Amgen 16
Adaptive Biotechnologies Enters into Agreement with Amgen for Multiple Myeloma 17
Adaptive Biotech Enters into Agreement with Amgen 18
Biocartis Partners with Amgen 19
Exosome Diagnostics Enters into Agreement with Amgen 20
Flatiron Health Partners with Amgen 21
Biocartis Enters into Agreement with Amgen 22
Dako Enters into Co-Development Agreement with Amgen for Companion Diagnostic 23
Dako Enters Into Co-Development Agreement With Amgen For Molecular Diagnostic Test 24
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 25
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 26
KineMed Enters Into Co-Development Agreement With Amgen For Kinetic Biomarkers Of Brain Proteinopathies 27
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 28
Dako Enters Into Co-Development Agreement With Amgen 29
Dako Enters Into Co-Development Agreement With Amgen 30
AstraZeneca Rumored To Merge With Amgen 31
Amgen Enters into Licensing Agreement with Unilife 32
Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 33
Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 34
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 35
Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 37
Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 38
Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 39
Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 40
Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 41
Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 42
Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 43
Unilife Raises USD30 Million in First Tranche of Private Placement of 6% Senior Secured Convertible Notes Due 2023 44
Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 46
Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 47
Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 48
Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 49
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 50
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 52
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 54
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 56
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 58
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 60
Amgen Inc, Key Competitors 62
Amgen Inc, Key Employees 63
Amgen Inc, Other Locations 65
Amgen Inc, Subsidiaries 67
Amgen Inc, Joint Venture 70

List of Figures
Amgen Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Amgen Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Amgen Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 8
Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Amgen Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

★海外企業調査レポート[Amgen Inc (AMGN)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Revalesio Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Revalesio Corp (Revalesio) is a developer of novel therapeutics for the treatment of inflammatory diseases. The company conducts research and development activities to develop therapeutics in the areas of respiratory, neuroscience and cardiovascular. Its product pipeline includes drugs targe …
  • Yuma Energy Inc (YUMA)：石油・ガス：M&Aディール及び事業提携情報
    Summary Yuma Energy Inc (Yuma) is an exploration and production company that offers acquisition, development, and exploration for conventional and unconventional oil and natural gas resources in the Gulf Coast and the Permian Basin of west Texas and California. The company designs and performs its o …
  • Copperbelt Energy Corporation Plc (CEC)：企業の財務・戦略的SWOT分析
    Copperbelt Energy Corporation Plc (CEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Eisai Co Ltd (4523)：企業の財務・戦略的SWOT分析
    Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Nigerian National Petroleum Corp：石油・ガス：M&Aディール及び事業提携情報
    Summary Nigerian National Petroleum Corp (NNPC) is a state-owned vertically integrated oil and gas company, which explores for, produces, markets and distributes crude oil, refined petroleum, petrochemicals and associated by-products. It operates through a network of refineries that produce products …
  • Barloworld Limited (BAW)：企業の財務・戦略的SWOT分析
    Barloworld Limited (BAW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Immatics Biotechnologies GmbH：企業のM&A・事業提携・投資動向
    Immatics Biotechnologies GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Immatics Biotechnologies GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Oncgnostics GmbH-医療機器分野：企業M&A・提携分析
    Summary Oncgnostics GmbH (Oncgnostics) is an in-vitro diagnostic company that specializes in the development of in-vitro diagnostic tests for the therapeutics area of cancer. The company’s pipeline offers GynTect technology, a system based on the detection of epigenetic biomarkers, mainly in the met …
  • Salvatore Ferragamo SpA (SFER)：企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Selvita SA (SLV)：企業の財務・戦略的SWOT分析
    Summary Selvita SA (Selvita) is a clinical stage biopharmaceutical company that develops small molecule therapies for the treatment of cancer. It is evaluating its pipeline candidates including SEL120, a selective CDK8 kinase inhibitor for the treatment of hematological malignancies and solid tumors …
  • Taneja Aerospace & Aviation Ltd.
    Taneja Aerospace & Aviation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Taneja Aerospace & Aviation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Coherus BioSciences Inc (CHRS)：製薬・医療：M&Aディール及び事業提携情報
    Summary Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used …
  • Binx Health Inc：企業の製品パイプライン分析
    Summary Binx Health Inc (Binx Health), a subsidiary of Binx Health Ltd, is a provider of near-patient and point of care (POC) testing solutions for women’s health. The company develops its proprietary, desktop, PCR-based point-of-care molecular diagnostic platform for diagnosis and treatment for chl …
  • The Hershey Co：企業のM&A・事業提携・投資動向
    The Hershey Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Hershey Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • ALS Limited (ALQ)-石油・ガス分野：企業M&A・提携分析
    Summary ALS Limited (ALS), formerly, Campbell Brothers Limited is a diversified testing service provider. The company provides testing services in the areas of minerals, life sciences, energy and industrial. It provides chemical and laboratory services, technical testing and inspection services supp …
  • South African Express Airways (Pty) Ltd
    South African Express Airways (Pty) Ltd - Strategy, SWOT and Corporate Finance Report Summary South African Express Airways (Pty) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Ergon, Inc.：石油・ガス：M&Aディール及び事業提携情報
    Summary Ergon Inc (Ergon) is an integrated energy company that carries out the exploration and production of crude oil and natural gas, processing, transportation and terminaling of crude oil, storage, marketing and distribution of specialty petroleum products. The company also manufactures and mark …
  • Moneysupermarket.com Group PLC (MONY)：企業の財務・戦略的SWOT分析
    Moneysupermarket.com Group PLC (MONY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • TIM SpA (TIT)：企業の財務・戦略的SWOT分析
    TIM SpA (TIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Bio Blast Pharma Ltd (ORPN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Bio Blast Pharma Ltd (Bioblast Pharma) is a clinical stage biotechnology company that discovers, delivers, and develops clinical therapies for patients with rare and ultra-rare genetic diseases. The company discovers and develops pipeline products using platforms such as cabaletta, a mutant …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆